Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1786453

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1786453

DNA Repair Drugs

PUBLISHED:
PAGES: 217 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Global DNA Repair Drugs Market to Reach US$19.5 Billion by 2030

The global market for DNA Repair Drugs estimated at US$8.3 Billion in the year 2024, is expected to reach US$19.5 Billion by 2030, growing at a CAGR of 15.2% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 17.2% CAGR and reach US$8.5 Billion by the end of the analysis period. Growth in the Hormonal Therapy segment is estimated at 11.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.2 Billion While China is Forecast to Grow at 14.2% CAGR

The DNA Repair Drugs market in the U.S. is estimated at US$2.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.0 Billion by the year 2030 trailing a CAGR of 14.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 14.3% and 12.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.9% CAGR.

Global DNA Repair Drugs Market - Key Trends & Drivers Summarized

Is Targeting DNA Repair Mechanisms Redefining Cancer Therapy Paradigms?

The study of DNA repair mechanisms has revolutionized oncology by uncovering vulnerabilities in cancer cells that can be therapeutically exploited. DNA repair drugs, which target specific enzymes and pathways involved in maintaining genomic integrity, are at the forefront of this transformation. Cancer cells often rely heavily on alternative DNA repair mechanisms due to defects in their primary repair pathways-making them uniquely sensitive to targeted inhibition. This concept, known as synthetic lethality, is the foundation for several FDA-approved drugs, such as PARP (poly ADP-ribose polymerase) inhibitors, which have demonstrated remarkable efficacy in treating BRCA-mutated ovarian, breast, pancreatic, and prostate cancers. The promise of DNA repair inhibitors lies in their ability to selectively kill tumor cells while sparing normal cells, reducing off-target toxicity commonly associated with chemotherapy. Beyond PARP, the industry is actively exploring a range of targets including ATM, ATR, DNA-PK, CHK1/2, and POLQ, each playing vital roles in the cellular response to DNA damage. These emerging therapies are being evaluated as both monotherapies and combination regimens alongside immunotherapy, radiation, and traditional chemotherapy. The precision and personalization of DNA repair-targeted therapies are enabling more effective treatment strategies tailored to individual genomic profiles. Biomarker-driven drug development is thus central to this field, as companion diagnostics are used to identify patients most likely to benefit. As understanding of the DNA damage response (DDR) network deepens, DNA repair drugs are redefining the way cancers are treated-shifting from a one-size-fits-all model to a highly targeted, mechanism-specific approach that marks a new era in oncology.

How Are Advances in Genomics and Biomarker Science Powering Drug Development?

Technological advancements in genomics, sequencing, and molecular diagnostics are driving the development and clinical application of DNA repair drugs by enabling precise identification of DNA repair deficiencies in tumors. High-throughput sequencing and next-generation sequencing (NGS) platforms are now widely used to detect mutations in genes like BRCA1/2, ATM, PALB2, and other components of the homologous recombination repair (HRR) and mismatch repair (MMR) pathways. These insights allow clinicians and researchers to stratify patients based on their genetic makeup and predict treatment response more accurately. Furthermore, the discovery of novel genomic signatures such as "BRCAness" or homologous recombination deficiency (HRD) scores is expanding the eligibility criteria for DNA repair drugs beyond just germline BRCA mutations. Liquid biopsies, which detect circulating tumor DNA (ctDNA), are also gaining traction as minimally invasive tools to monitor treatment response and resistance in real time. Biomarker-guided drug development has become a key strategy for pharmaceutical companies, helping them design smarter clinical trials with enriched patient populations and higher success probabilities. Moreover, CRISPR-Cas9 gene editing is being used in preclinical models to better understand the role of specific DNA repair genes and their contribution to cancer progression, paving the way for the identification of new therapeutic targets. In silico modeling and AI-driven drug discovery platforms are also accelerating the identification of small-molecule inhibitors with higher selectivity and potency. These technological synergies are not only refining drug design but also enabling more robust clinical pipelines, setting the stage for a new generation of DNA repair drugs tailored to molecularly defined tumor subtypes.

Is the Expanding Therapeutic Scope Beyond Cancer Broadening Market Potential?

While oncology remains the primary application for DNA repair drugs, the potential therapeutic scope of these agents is expanding to include a variety of non-oncological conditions, which is significantly broadening the market’s potential. DNA repair mechanisms play a crucial role in aging, inflammation, and neurodegeneration-areas where genomic instability contributes to disease onset and progression. In neurodegenerative disorders like Alzheimer’s, Parkinson’s, and Huntington’s disease, growing evidence suggests that defects in DNA damage response pathways may contribute to neuronal death and cognitive decline. Researchers are investigating whether modulating DNA repair enzymes could slow disease progression or enhance neuroprotection. Similarly, autoimmune diseases and rare genetic disorders such as ataxia-telangiectasia and Fanconi anemia-characterized by inherent DNA repair deficiencies-are emerging as new therapeutic frontiers for DNA repair modulation. Moreover, radiation exposure, whether from cancer therapy or environmental sources, induces DNA damage, and DNA repair enhancers could be developed to protect healthy tissues or mitigate long-term effects. Pharmaceutical companies are exploring dual-use molecules that serve both as inhibitors in oncology and as protectants in other diseases, depending on how they are applied. This therapeutic flexibility increases the commercial attractiveness of DNA repair drug candidates, encouraging broader R&D investment. The rise of aging research, particularly focused on genome maintenance as a pillar of healthy longevity, is drawing attention to DNA repair pathways as potential intervention points. As the scientific community continues to explore the interconnectedness of DNA damage, chronic disease, and cellular aging, the relevance of DNA repair drugs is expanding far beyond cancer, unlocking a multitude of high-value clinical applications.

What Are the Core Drivers Fueling Growth in the DNA Repair Drugs Market?

The growth in the DNA repair drugs market is driven by several factors deeply rooted in scientific innovation, precision medicine, and evolving therapeutic strategies. A major driver is the growing prevalence of cancer worldwide, which is increasing demand for more targeted and less toxic therapies. DNA repair inhibitors, particularly PARP inhibitors, have already shown success in improving survival outcomes in BRCA-mutated and homologous recombination-deficient tumors, leading to rising adoption and new indications. The push toward personalized medicine is another key factor-clinicians are increasingly using molecular profiling to identify patients with DNA repair gene mutations who can benefit from these therapies. Advances in sequencing technologies and companion diagnostics are making such precision targeting more feasible and cost-effective. Additionally, the pharmaceutical industry’s expanding focus on combination therapies is playing a critical role in market growth, with DNA repair drugs being used alongside immune checkpoint inhibitors, chemotherapy, and radiation to enhance efficacy and overcome resistance. The increasing number of clinical trials exploring inhibitors of ATR, ATM, DNA-PK, and other DDR targets reflects a robust and growing development pipeline. Moreover, strategic collaborations between biotech startups and large pharmaceutical companies are accelerating the translation of early-stage research into viable therapeutic candidates. Regulatory bodies are also supporting innovation through fast-track designations, breakthrough therapy approvals, and expanded label indications for approved drugs. The emergence of real-world evidence from post-marketing studies is helping validate the long-term benefits of these treatments and guiding reimbursement decisions. Finally, public and private investments in oncology and aging research are creating a fertile environment for continued exploration of DNA repair biology, further propelling market momentum. These interconnected drivers are collectively positioning DNA repair drugs as a cornerstone of next-generation therapeutic strategies across oncology and beyond.

SCOPE OF STUDY:

The report analyzes the DNA Repair Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Breast Cancer Drugs Therapy (Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy, Immunotherapy Therapy); Breast Cancer Drugs Cancer Type (Hormone Receptor Type, HER2+ Type); Breast Cancer Drugs Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 34 Featured) -

  • AbbVie Inc.
  • Agios Pharmaceuticals, Inc.
  • Allarity Therapeutics A/S
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BioMarin Pharmaceutical Inc.
  • Boehringer Ingelheim GmbH
  • Breakpoint Therapeutics
  • Bristol-Myers Squibb Company
  • Clovis Oncology
  • Eli Lilly and Company
  • FoRx Therapeutics
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc.
  • Lantern Pharma Inc.
  • Luciole Pharmaceuticals
  • Merck & Co., Inc.
  • Novartis AG

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Product Code: MCP30559

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • DNA Repair Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Advances in Cancer Genomics Throw the Spotlight on DNA Repair Pathways as Therapeutic Targets
    • Success of PARP Inhibitors Propels Growth and Validates the DNA Repair Drug Development Model
    • Rising Prevalence of BRCA and HRD-Related Cancers Strengthens Business Case for Synthetic Lethality-Based Therapies
    • Expansion of Companion Diagnostics Accelerates Adoption of Biomarker-Guided DNA Repair Treatments
    • Integration of DNA Repair Drugs into Combination Therapy Regimens Spurs Broader Oncology Use Cases
    • Growing Focus on Tumor-Specific Vulnerabilities Drives Development of Novel DDR (DNA Damage Response) Inhibitors
    • Emerging Targets Beyond PARP, Including ATR, ATM, DNA-PK, and POLQ, Expand Addressable Therapeutic Pipeline
    • Increased Investment in Precision Oncology Programs Fuels R&D Activity in DNA Repair Modulators
    • Use of CRISPR and Functional Genomics in Drug Discovery Enhances Target Validation and Pipeline Innovation
    • Real-World Evidence and Post-Market Data Strengthen Confidence in Long-Term Clinical Benefits
    • Growing Applications in Prostate, Pancreatic, and Ovarian Cancers Drive Indication Expansion
    • Potential Utility in Non-Oncological Conditions Opens New Growth Frontiers for DNA Repair Modulation
    • Global Rise in Personalized Medicine Initiatives Generates Sustained Demand for Genomic Repair Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World DNA Repair Drugs Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for DNA Repair Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for DNA Repair Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for DNA Repair Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Hormonal Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Chemotherapy Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Chemotherapy Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Chemotherapy Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Immunotherapy Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Immunotherapy Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Immunotherapy Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hormone Receptor Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hormone Receptor Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Hormone Receptor Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for HER2+ Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for HER2+ Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for HER2+ Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • DNA Repair Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Percentage Breakdown of Value Sales for Hormone Receptor Type and HER2+ Type for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Percentage Breakdown of Value Sales for Hormone Receptor Type and HER2+ Type for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • JAPAN
    • DNA Repair Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Percentage Breakdown of Value Sales for Hormone Receptor Type and HER2+ Type for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CHINA
    • DNA Repair Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Percentage Breakdown of Value Sales for Hormone Receptor Type and HER2+ Type for the Years 2015, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • EUROPE
    • DNA Repair Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for DNA Repair Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for DNA Repair Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for DNA Repair Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Percentage Breakdown of Value Sales for Hormone Receptor Type and HER2+ Type for the Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • FRANCE
    • DNA Repair Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Percentage Breakdown of Value Sales for Hormone Receptor Type and HER2+ Type for the Years 2015, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • GERMANY
    • DNA Repair Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Percentage Breakdown of Value Sales for Hormone Receptor Type and HER2+ Type for the Years 2015, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Percentage Breakdown of Value Sales for Hormone Receptor Type and HER2+ Type for the Years 2015, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • DNA Repair Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Percentage Breakdown of Value Sales for Hormone Receptor Type and HER2+ Type for the Years 2015, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Rest of Europe Historic Review for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Rest of Europe 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy for the Years 2015, 2025 & 2030
    • TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Rest of Europe Historic Review for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Rest of Europe 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Percentage Breakdown of Value Sales for Hormone Receptor Type and HER2+ Type for the Years 2015, 2025 & 2030
    • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Europe Historic Review for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Rest of Europe 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • DNA Repair Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Asia-Pacific Historic Review for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Asia-Pacific 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy for the Years 2015, 2025 & 2030
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific Historic Review for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Asia-Pacific 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Percentage Breakdown of Value Sales for Hormone Receptor Type and HER2+ Type for the Years 2015, 2025 & 2030
    • TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Asia-Pacific Historic Review for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Asia-Pacific 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of World Historic Review for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of World 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of World Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of World Historic Review for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of World 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Percentage Breakdown of Value Sales for Hormone Receptor Type and HER2+ Type for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of World Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of World Historic Review for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of World 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030

IV. COMPETITION

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!